Tech Company Financing Transactions
Orbis Medicines Funding Round
Orbis Medicines, operating out of Copenhagen, received $93 million from New Enterprise Associates, Cormorant Capital and EIFO.
Transaction Overview
Company Name
Announced On
1/6/2025
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the development of pipeline of oral macrocycle drugs, called 'nCycles,' focused on validated blockbuster biologic targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Copenhagen, Undisclosed
Denmark
Copenhagen, Undisclosed
Denmark
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to define a new era for macrocycle drugs and make great contributions to medicine. We are bringing together a world-class team to make this possible. Our broad pipeline is initially focused on delivering oral macrocycle candidates against targets validated by blockbuster biologic drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Morten Dossing
Chief Technical Officer
Sevan Habeshian
Vice President
Daniela Brodbeck
Vice President
Daniel Greve
VP - Bus. Development
Simon Feldbaek
Browse more venture capital transactions:
Prev: 1/6/2025: PBS Biotech venture capital transaction
Next: 1/6/2025: JAN3 venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs